248 related articles for article (PubMed ID: 36354732)
1. Targeting CAM-DR and Mitochondrial Transfer for the Treatment of Multiple Myeloma.
Suzuki R; Ogiya D; Ogawa Y; Kawada H; Ando K
Curr Oncol; 2022 Nov; 29(11):8529-8539. PubMed ID: 36354732
[TBL] [Abstract][Full Text] [Related]
2. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism.
Kobune M; Chiba H; Kato J; Kato K; Nakamura K; Kawano Y; Takada K; Takimoto R; Takayama T; Hamada H; Niitsu Y
Mol Cancer Ther; 2007 Jun; 6(6):1774-84. PubMed ID: 17575106
[TBL] [Abstract][Full Text] [Related]
3. [The mechanisms of drug resistance via the interaction of myeloma cells with stromal cells].
Kikuchi J; Furukawa Y
Nihon Rinsho; 2015 Jan; 73(1):57-61. PubMed ID: 25626305
[TBL] [Abstract][Full Text] [Related]
4. Microenvironment drug resistance in multiple myeloma: emerging new players.
Di Marzo L; Desantis V; Solimando AG; Ruggieri S; Annese T; Nico B; Fumarulo R; Vacca A; Frassanito MA
Oncotarget; 2016 Sep; 7(37):60698-60711. PubMed ID: 27474171
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.
Furukawa Y; Kikuchi J
Int J Hematol; 2016 Sep; 104(3):281-92. PubMed ID: 27411688
[TBL] [Abstract][Full Text] [Related]
7. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase.
Schmidmaier R; Baumann P; Simsek M; Dayyani F; Emmerich B; Meinhardt G
Blood; 2004 Sep; 104(6):1825-32. PubMed ID: 15161667
[TBL] [Abstract][Full Text] [Related]
8. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
[TBL] [Abstract][Full Text] [Related]
9. Elucidating the expression and function of Numbl during cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma (MM).
Huang Y; Huang X; Cheng C; Xu X; Liu H; Yang X; Yao L; Ding Z; Tang J; He S; Wang Y
BMC Cancer; 2019 Dec; 19(1):1269. PubMed ID: 31888545
[TBL] [Abstract][Full Text] [Related]
10. CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.
Waldschmidt JM; Simon A; Wider D; Müller SJ; Follo M; Ihorst G; Decker S; Lorenz J; Chatterjee M; Azab AK; Duyster J; Wäsch R; Engelhardt M
Br J Haematol; 2017 Oct; 179(1):36-49. PubMed ID: 28670693
[TBL] [Abstract][Full Text] [Related]
11. ADP-ribosylation factor 1 (ARF1) takes part in cell proliferation and cell adhesion-mediated drug resistance (CAM-DR).
Xu X; Wang Q; He Y; Ding L; Zhong F; Ou Y; Shen Y; Liu H; He S
Ann Hematol; 2017 May; 96(5):847-858. PubMed ID: 28238095
[TBL] [Abstract][Full Text] [Related]
12. Preferential transfer of mitochondria from endothelial to cancer cells through tunneling nanotubes modulates chemoresistance.
Pasquier J; Guerrouahen BS; Al Thawadi H; Ghiabi P; Maleki M; Abu-Kaoud N; Jacob A; Mirshahi M; Galas L; Rafii S; Le Foll F; Rafii A
J Transl Med; 2013 Apr; 11():94. PubMed ID: 23574623
[TBL] [Abstract][Full Text] [Related]
13. The role of metabolism and tunneling nanotube-mediated intercellular mitochondria exchange in cancer drug resistance.
Hekmatshoar Y; Nakhle J; Galloni M; Vignais ML
Biochem J; 2018 Jul; 475(14):2305-2328. PubMed ID: 30064989
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.
Yang WC; Lin SF
Biomed Res Int; 2015; 2015():341430. PubMed ID: 26649299
[TBL] [Abstract][Full Text] [Related]
15. Integrin-mediated drug resistance in multiple myeloma.
Damiano JS; Dalton WS
Leuk Lymphoma; 2000 Jun; 38(1-2):71-81. PubMed ID: 10811449
[TBL] [Abstract][Full Text] [Related]
16. CD38-Driven Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma.
Marlein CR; Piddock RE; Mistry JJ; Zaitseva L; Hellmich C; Horton RH; Zhou Z; Auger MJ; Bowles KM; Rushworth SA
Cancer Res; 2019 May; 79(9):2285-2297. PubMed ID: 30622116
[TBL] [Abstract][Full Text] [Related]
17. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
Hazlehurst LA; Enkemann SA; Beam CA; Argilagos RF; Painter J; Shain KH; Saporta S; Boulware D; Moscinski L; Alsina M; Dalton WS
Cancer Res; 2003 Nov; 63(22):7900-6. PubMed ID: 14633719
[TBL] [Abstract][Full Text] [Related]
18. Stromal Support of Metabolic Function through Mitochondrial Transfer in Multiple Myeloma.
Boise LH; Shanmugam M
Cancer Res; 2019 May; 79(9):2102-2103. PubMed ID: 31043428
[TBL] [Abstract][Full Text] [Related]
19. The role of ubiquitin-specific protease 14 (USP14) in cell adhesion-mediated drug resistance (CAM-DR) of multiple myeloma cells.
Xu X; Liu J; Shen C; Ding L; Zhong F; Ouyang Y; Wang Y; He S
Eur J Haematol; 2017 Jan; 98(1):4-12. PubMed ID: 26710889
[TBL] [Abstract][Full Text] [Related]
20. Cell adhesion induces overexpression of chromodomain helicase/ATPase DNA binding protein 1-like gene (CHD1L) and contributes to cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma cells.
Xu X; He Y; Miao X; Wu Y; Han J; Wang Q; Liu J; Zhong F; Ou Y; Wang Y; He S
Leuk Res; 2016 Aug; 47():54-62. PubMed ID: 27258734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]